Navigation Links
Live Webinar on Protection of Phase 1 Research Volunteers
Date:1/10/2013

Toronto, Canada (PRWEB) January 10, 2013

Join esteemed speakers, Dr. Agnes Klein, MD, MPH, Director, Centre for the Evaluation of Radiopharmaceuticals and Biotherapeutic Products in the Biologics and Genetic Therapies Directorate, Health Canada, and Dr. Richard Larouche, BPharm, MD, Director, Medical Affairs, Early Stage Development, Pharmanet/i3, as they examine the current risks and approaches.

The outbreak of new infectious diseases on a global scale such as SARS, swine flu (H1N1), avian flu (H1N5), received wide press coverage and caused panic in the general population. As of November 30, 2012, there were nine confirmed cases of a SARS-like illness in the Middle East, five of which were fatal. When the next pandemic is due is unknown, but it is only a matter of time before the next pandemic is a reality. Simultaneously, infectious diseases such as TB, polio, rubella, pertussis, etc., are on the rise in developing countries as well as the West.

Phase 1 research typically involves confinement of volunteers in a group living setting, sometimes for extended periods, thus putting them at risk of exposure to communicable disease carried by fellow subjects or clinic staff. First-in-humans research with compounds targeting the immune system, or special populations such as the elderly or those with renal or hepatic impairment, represent even greater potential risks.

Dr. Klein will discuss Health Canada’s approach and requirements. Dr. Larouche will discuss the practical dimensions of the problem, and what must be done at the clinic level, over and above regulatory requirements.

For more information or to register go to http://xtks.in/xto552irb.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Xtalks (powered by Honeycomb Worldwide Inc.)
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10304668.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Northeastern University Nanomanufacturing Center Director Ahmed Busnaina to Present Webinar on “The Democratization of Manufacturing”
2. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
3. Best Practices, LLC Issues New Report and Webinar on Managing Healthcare Reform through Effective Engagement with the Government Ecosystem
4. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
5. The Veterinary Bioscience Institute Announces an Amazing Series of 41 Webinars for 2013
6. The Veterinary Bioscience Institute Announces its January 2013 Webinar Schedule
7. Webinar on Clinical, Regulatory and Commercialization Strategies for Rare Diseases
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
10. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
11. Biotechnology and Environmental Protection at this Years ACHEMA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has received ... SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure ... periods of rest. A lightweight, non-invasive monitor is placed on the belly of ...
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
Breaking Biology News(10 mins):